Published in Arch Neurol on April 01, 2010
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Psychedelics. Pharmacol Rev (2016) 1.00
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014) 0.95
Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics (2014) 0.90
The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res (2013) 0.86
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Positron emission tomography neuroimaging in Parkinson's disease. Am J Transl Res (2011) 0.85
An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother (2011) 0.85
Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal (2011) 0.85
Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol (2013) 0.82
An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease. J Neural Transm (Vienna) (2013) 0.79
The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. PLoS One (2012) 0.78
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochem Res (2014) 0.78
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl) (2017) 0.76
New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinsons Dis (2011) 0.76
Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells. Expert Rev Neurother (2015) 0.75
Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis. BJPsych Open (2015) 0.75
The psychosis spectrum in Parkinson disease. Nat Rev Neurol (2017) 0.75
Advances in functional neuroimaging in dementias and potential pitfalls. Neurol Int (2012) 0.75
Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists. Neurodegener Dis Manag (2016) 0.75
Neuropsychiatric symptoms in untreated Parkinson's disease. Neuropsychiatr Dis Treat (2017) 0.75
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. Curr Neuropharmacol (2016) 0.75
Affective disorders in Parkinson's disease. Curr Opin Neurol (2013) 0.75
Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis? NPJ Parkinsons Dis (2017) 0.75
New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease. Curr Pharmacol Rep (2016) 0.75
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry (2006) 2.21
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol (2007) 2.01
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry (2004) 2.00
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Functional role of the basal ganglia in the planning and execution of actions. Ann Neurol (2006) 1.96
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study. Neurosci Lett (2007) 1.86
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord (2011) 1.70
An automated method for the extraction of regional data from PET images. Psychiatry Res (2006) 1.67
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol (2008) 1.58
Consensus paper: combining transcranial stimulation with neuroimaging. Brain Stimul (2009) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain (2006) 1.51
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry (2010) 1.50
Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study. Arch Neurol (2009) 1.49
Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci (2012) 1.48
Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem (2006) 1.42
Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry (2007) 1.40
Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord (2009) 1.38
First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology (2007) 1.38
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry (2003) 1.30
Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry (2004) 1.27
Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab (2006) 1.26
Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry (2009) 1.25
High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry (2005) 1.24
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev (2013) 1.23
Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol (2005) 1.23
Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA. J Cereb Blood Flow Metab (2012) 1.22
rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One (2009) 1.22
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry (2004) 1.21
Increased stress-induced dopamine release in psychosis. Biol Psychiatry (2011) 1.20
Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry (2010) 1.20
Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry (2008) 1.19
The neural circuitry of executive functions in healthy subjects and Parkinson's disease. Neuropsychopharmacology (2010) 1.18
Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry (2006) 1.15
The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction (2013) 1.15
Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study. Hum Brain Mapp (2009) 1.13
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci (2008) 1.12
Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2013) 1.12
Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. PLoS One (2009) 1.12
Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol (2009) 1.10
Dorsolateral prefrontal and orbitofrontal cortex interactions during self-control of cigarette craving. Proc Natl Acad Sci U S A (2013) 1.10
Continuous theta burst stimulation of right dorsolateral prefrontal cortex induces changes in impulsivity level. Brain Stimul (2009) 1.10
Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. Arch Neurol (2007) 1.10
Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab (2006) 1.10
In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol (2002) 1.08
Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) (2002) 1.07
Striatal dopamine release during performance of executive functions: A [(11)C] raclopride PET study. Neuroimage (2006) 1.07
Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. Bioorg Med Chem Lett (2005) 1.07
[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl Med Biol (2011) 1.06
Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis (2012) 1.05
Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab (2011) 1.05
Theta burst stimulation-induced inhibition of dorsolateral prefrontal cortex reveals hemispheric asymmetry in striatal dopamine release during a set-shifting task: a TMS-[(11)C]raclopride PET study. Eur J Neurosci (2008) 1.05
Potentiation of gamma oscillatory activity through repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex. Neuropsychopharmacology (2009) 1.05
Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol (2003) 1.03
The serotonergic system in Parkinson's disease. Prog Neurobiol (2011) 1.02
The effect of handedness on cortical motor activation during simple bilateral movements. Neuroimage (2006) 1.02
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J (2005) 1.02
Synthesis and in vitro evaluation of derivatives of the β₁-adrenergic receptor antagonist HX-CH 44. Bioorg Med Chem Lett (2011) 1.01
Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis (2010) 1.01
D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology (2008) 1.01
Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imaging (2002) 1.01
Deep Brain Stimulation and the Search for Identity. Neuroethics (2011) 1.00
A positron emission tomography study of short- and long-term treatment effects on functional brain activation in adults who stutter. J Fluency Disord (2003) 1.00
Direct fixation of [(11)C]-CO(2) by amines: formation of [(11)C-carbonyl]-methylcarbamates. Org Biomol Chem (2009) 0.99
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol (2003) 0.99
Extrastriatal dopaminergic dysfunction in tourette syndrome. Ann Neurol (2010) 0.99
Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry (2011) 0.98
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry (2009) 0.97
Morphometric correlation of impulsivity in medial prefrontal cortex. Brain Topogr (2012) 0.97
Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct Funct (2011) 0.97
Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse (2004) 0.97
The neural response to transcranial magnetic stimulation of the human motor cortex. II. Thalamocortical contributions. Exp Brain Res (2006) 0.96